Training the next generation of pharmacometric modelers: a multisector perspective.
Education
Modeling and simulation
Pharmacometrics
Journal
Journal of pharmacokinetics and pharmacodynamics
ISSN: 1573-8744
Titre abrégé: J Pharmacokinet Pharmacodyn
Pays: United States
ID NLM: 101096520
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
13
04
2023
accepted:
17
07
2023
medline:
26
2
2024
pubmed:
13
8
2023
entrez:
13
8
2023
Statut:
ppublish
Résumé
The current demand for pharmacometricians outmatches the supply provided by academic institutions and considerable investments are made to develop the competencies of these scientists on-the-job. Even with the observed increase in academic programs related to pharmacometrics, this need is unlikely to change in the foreseeable future, as the demand and scope of pharmacometrics applications keep expanding. Further, the field of pharmacometrics is changing. The field largely started when Lewis Sheiner and Stuart Beal published their seminal papers on population pharmacokinetics in the late 1970's and early 1980's and has continued to grow in impact and use since its inception. Physiological-based pharmacokinetics and systems pharmacology have grown rapidly in scope and impact in the last decade and machine learning is just on the horizon. While all these methodologies are categorized as pharmacometrics, no one person can be an expert in everything. So how do you train future pharmacometricians? Leading experts in academia, industry, contract research organizations, clinical medicine, and regulatory gave their opinions on how to best train future pharmacometricians. Their opinions were collected and synthesized to create some general recommendations.
Identifiants
pubmed: 37573528
doi: 10.1007/s10928-023-09878-4
pii: 10.1007/s10928-023-09878-4
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
5-31Subventions
Organisme : Medical Research Council
ID : MR/M008665/1
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Benet LZ, Rowland M (1982) Pharmacometrics: a new journal section. J Pharmacokinetic Pharmacodynam 10:349–350
doi: 10.1007/BF01065167
Michelet R, Aulin LBS, Borghardt JM, Dalla Costa T, Denti P, Ibarra M, Ma G, Meibohm B, Pillai GC, Schmidt S, Hennig S, Kloft C (2023) Barriers to global pharmacometrics: educational challenges and opportunities across the globe. CPT: Pharmacometrics Syst Pharmacol 12:743–747
pubmed: 36960632
Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR (2008) Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol 48:632–639
pubmed: 18440922
doi: 10.1177/0091270008315318
Gieschke R, Steimer JL (2000) Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokin 25:49–58
doi: 10.1007/BF03190058
Lee WH, Fujiwara M (1971) Pharmacometrics of guinea-pig’s gallbladder in vitro. Taiwan Yi Xue Hui Za Zhi 70:687–696
pubmed: 5293622
Levy G (1966) Kinetics of pharmacologic effects. Clin Pharmacol Ther 7:362–372
pubmed: 5937003
doi: 10.1002/cpt196673362
Karlsson MO (2016). Big world challenges for pharmacometrics. World Conference on Pharmacometrics, Brisbane, Australia.
Gobburu JVS (2022) Future of pharmacometrics: predictive healthcare analytics. Br J Clin Pharmacol 88:1427–1429
pubmed: 33080071
doi: 10.1111/bcp.14618
Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I (2019) Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther 105:899–911
pubmed: 30653670
doi: 10.1002/cpt.1363
Hughes DM, Goswami S, Keizer RJ, Hughes M-SA, Faldasz JD (2020) Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population. J Antimicrob Chemother 75:434–437
pubmed: 31670812
Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, Kashuba ADM, Lee CR, Morbitzer K, Patterson JH, Wiltshire T, Easter J, Savage SW, Powell RJ (2017) Precision dosing: public health need, proposed framework, and anticipated impact. Clin Transl Sci 10:443–454
pubmed: 28875519
pmcid: 5698804
doi: 10.1111/cts.12490
Manolis E, Musuamba FT, Karlsson K (2020) Regulatory considerations for building an in silico clinical pharmacology backbone by 2030. Clin Pharmacol Ther 107:746–748
pubmed: 32010966
doi: 10.1002/cpt.1772
Karatza E, Yakovleva T, Adams K, Rao GG, Ait-Oudhia S (2022) Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative. J Pharmacokinetic Pharmacodynam 2022:397–400
doi: 10.1007/s10928-022-09809-9
Mentre F, Friberg LE, Duffull S, French J, Lauffenburger DA, Li L, Mager DE, Sinha V, Sobie E, Zhao P (2020) Pharmacometrics and systems pharmacology 2030. Clin Pharmacol Ther 107:76–78
pubmed: 31758700
doi: 10.1002/cpt.1683
van der Graaf PH, Giacomini KM (2020) Clinical pharmacology & therapeutics 2030. Clin Pharmacol Ther 107:13–16
pubmed: 31863685
doi: 10.1002/cpt.1705
Bonate PL (2014) Be a model communicator: and sell your models to anyone. KDP Publishing (Amazon), Seattle
Lesko, L. J. (2009). Formation of the Division of Pharmacometrics within Office of Clinical Pharmacology at FDA. ( https://www.mail-archive.com/nmusers@globomaxnm.com/msg01493.html
Akcha M, Bartels C, Bornkamp B, Bretz F, Coello N, Dumortier T, Looby M, Sander O, Schmidli H, Steimer J-L, Vong C (2021) Estimands—what they are and why they are important for pharmacometricians. CPT Pharmacometrics Syst Pharmacol 10:279–282
doi: 10.1002/psp4.12617
Jaki T, Gordon A, Forster P, Bijnens L, Bornkamp B, Brannath W, Fontana R, Gasparini M, Hampson LV, Jacobs T, Jones B, Paoletti X, Posch M, Titman A, Vonk R, Koenig F (2018) A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17:593–606
pubmed: 29984474
pmcid: 6174936
doi: 10.1002/pst.1873
Jaki T, Gordon A, Forster P, Bijnens L, Bornkamp B, Brannath W, Fontana R, Gasparini M, Hampson LV, Jacobs T, Jones B, Paoletti X, Posch M, Titman A, Vonk R, Koenig F (2019) Response to comments on Jaki et al., a proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 18:284–286
pubmed: 30868716
doi: 10.1002/pst.1942
Krause A, Kloft C, Huisinga W, Karlsson MO, Pinheiro J, Bies R, Rogers J, Mentre F, Musser BJ, ASA Special Interest Group on Statistics and Pharmacometrics/ISoP Special Interest Group on Statistics and Pharmacometrics (2019) Comment on Jaki et al., a proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 18:278–281
pubmed: 30932340
doi: 10.1002/pst.1940
Dingemanse J, Krause A (2017) Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development. Eur J Pharm Sci 109S:S53–S58
pubmed: 28535992
doi: 10.1016/j.ejps.2017.05.042
Lott D, Lehr T, Dingemanse J, Krause A (2018) Modeling tolerance development for the effect on heart rate of the selective S1P1 receptor modulator ponesimod. Clin Pharmacol Ther 103:1083–1092
pubmed: 28913826
doi: 10.1002/cpt.877
Krause A, Lowe PJ (2014) Visualization and communication of pharmacometric models with Berkeley Madonna. CPT Pharmacometrics Syst Pharmacol 3:e116
pubmed: 24872204
pmcid: 4055786
doi: 10.1038/psp.2014.13
Lixoft (2020). Simulx Documentation. ( https://simulx.lixoft.com/
R Studio, Inc. (2013). Shiny: Web Application Framework for R. ( http://shiny.rstudio.com/
Vlasakakis G, Comets E, Keunecke A, Gueorguieva I, Magni P, Terranova N, Della Pasqua O, de Lange EC, Kloft C (2013) White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. CPT Pharmacometrics Syst Pharmacol 2:e40
pubmed: 23887723
pmcid: 3674326
doi: 10.1038/psp.2013.16
Salas-Vallina A, Alegra J, Fernandez Guerrero R (2018) Happiness at work in knowledge-intensive contexts: opening the research agenda. Eur Res ManagBus Econ 24:149–159
Sinek S (2009) Start with why: how great leaders inspire everyone to take action. Penguin, New York
Anziano R, Milligan PA (2021) Model informed drug development: collaboration through a common framework. Clin Pharmacol Ther 110:1165–1167
pubmed: 33111309
doi: 10.1002/cpt.2066
Barrett JS (2008) The role of quantitative pharmacology in an academic translational research environment. AAPS J 10:9–14
pubmed: 18446501
pmcid: 2751447
doi: 10.1208/s12248-007-9002-7
Romero K, Corrigan B, Tornoe CW, Gobburu JVS, Danhof M, Gillespie WR, Gastonguay MR, Meibohm B, Derendorf H (2010) Pharmacometrics as a discipline is entering the “industrialization” phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol 50(Suppl 9):9S-19S
pubmed: 20881213
Brundage RC, Pfister M, D’Argenio D, Gastonguay M, Miller R, Tannenbaum S (2010) ACoP: The tools, carpenters, and architects building the discipline of pharmacometrics. J Clin Pharmacol 50(Suppl 9):7S-8S
pubmed: 20881212
Pfister M, Brundage RC, Gastonguay M, Miller R, Tannenbaum SJ, D’Argenio DZ (2010) Defining the future of pharmacometrics: the American Society of Pharmacometrics. J Clin Pharmacol 50(9):158S
pubmed: 20881230
Bruno R, Mentre F, Tannenbaum S, Wang Y, Corrigan B, Mager DE (2014) The ISoP standards and best practices committee. Clin Pharmacol Ther 95:581–582
pubmed: 24842638
doi: 10.1038/clpt.2014.65
Holford N, Karlsson MO (2007) Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum. Clin Pharmacol Ther 82:103–105
pubmed: 17495873
doi: 10.1038/sj.clpt.6100231
Brouwer KLR, Schmidt S, Floren LC, Johnson JA (2020) Clinical pharmacology education—the decade ahead. Clin Pharmacol Ther 107:37–39
pubmed: 31709518
doi: 10.1002/cpt.1652
Venkatakrishnan K, Zheng S, Mustante CJ, Jin JY, Riggs MR, Krishnaswami S, Visser SAG (2020) Toward progress in quantitative translational medicine: a call to action. Clin Pharmacol Ther 107:85–88
pubmed: 31750932
doi: 10.1002/cpt.1687
Neely M, Jelliffe R (2008) Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol 48:1081–1091
pubmed: 18635757
pmcid: 2724306
doi: 10.1177/0091270008321789
Neely M, Jelliffe R (2010) Individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol 50:842–847
pubmed: 20154293
doi: 10.1177/0091270009356572
Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny J-L, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A (2017) Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. Clin Pharmacol Ther 101:646–656
pubmed: 28182269
doi: 10.1002/cpt.659
Vinks AA, Peck RW, Neely M, Mould DR (2020) Development and implementation of electronic health record-integrated model-informed clinical descision support tools for the precision dosing of drugs. Clin Pharmacol Ther 107:129–135
pubmed: 31621071
doi: 10.1002/cpt.1679
Zhang L, Allerheilegen SRB, Lalonde R, Stanski D, Pfister M (2010) Fostering culture and optimizing organizational structure for implementing model-based drug development. J Clin Pharmacol 50(9):146S-150S
pubmed: 20881228
Barrett JS, Romero K, Rayner C, Gastonguay M, Pillai C, Tannenbaum S, Kern S, Selich M, Francisco D, Zinneh I (2023). A modern curriculum for training scientists in model-informed drug development (MIDD): initial proposal developed in support of FDA grant to train regulatory scientists. Clin Pharmacol Ther (in press).
Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499–505
pubmed: 9468466
doi: 10.1056/NEJM199802193380803
Waterterdal Syversen S, Kaasen Jorgensen K, Lovik Goll G, Kirkesaether Brun M, Sandanger O et al (2021) Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA 326:2375–2384
pubmed: 34932077
doi: 10.1001/jama.2021.21316
Ewoldt TMJ, Abdulla A, Rietdijk WJR, Muller AE, de Winter BCM, Hunfeld NGM, Purmer IM, van Vliet P, Wils E-J, Haringman J, Draisma A, Rijpstra TA, Karakus A, Gommers D, Endeman H, Koch BCP (2022) Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial. Intensive Care Med 48:1760–1771
pubmed: 36350354
pmcid: 9645317
doi: 10.1007/s00134-022-06921-9
Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Beasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler VG, Holland TL (2020) The emperor’s new clothes: PRospective observational evaluation of the association between Initial vancomycin exposure and failure rates among ADult HospitalizEd patients With methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE). Clin Infect Dis 70:1536–1545
pubmed: 31157370
doi: 10.1093/cid/ciz460
Standing J (2017) Understanding and applying pharmacometric modelling and simulation in clinical practice and research. Br J Clin Pharmacol 83:247–254
pubmed: 27567102
doi: 10.1111/bcp.13119
Ito K, Murphy D (2013) Application of ggplot2 to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol 16:e79
Fidler M, Hooijnaijers R, Schoemaker R, Wilkins JJ, Xiong Y, Wang W (2021) R and nlmixr as a gateway between statistics and pharmacometrics. CPT Pharmacometrics Syst Pharmacol 10:283–285
pubmed: 33951757
pmcid: 8099435
doi: 10.1002/psp4.12618
Fidler M, Wilkins JJ, Hooijnaijers R, Post TM, Schoemaker R, Trame MJ, Xiong Y, Wang W (2019) Nonlinear mixed-effects model development and simulation using nlmixr and related R open-source packages. CPT Pharmacometrics Syst Pharmacol 8:621–633
pubmed: 31207186
pmcid: 6765694
doi: 10.1002/psp4.12445
Ogami C, Tsuji Y, Seki H, Kawano H, To H, Matsumoto Y, Hosono H (2021) An artificial neural network-pharmacokinetic model and its interpretation using Shapley additive explanations. CPT Pharmacometrics Syst Pharmacol 10:760–768
pubmed: 33955705
pmcid: 8302242
doi: 10.1002/psp4.12643
Standing J, Anderson BJ, Holford NHG, Lutsar I, Metsvaht T (2015) Comment on pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. Clin Pharmacokinet 54:1287–1288
pubmed: 26547309
doi: 10.1007/s40262-015-0344-5
Germovsek E, Lutsar I, Kipper K, Karlsson MO, Planche T, Chazallon C, Meyer L, Trafojer UMT, Metsvaht T, Fournier I, Sharland M, Heath P, Standing JF, NeoMero Consortium (2018) Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. J Antimicrob Chemother 73:1908–1916
pubmed: 29684147
pmcid: 6005047
doi: 10.1093/jac/dky128
Kane Z, Gastine S, Obiero C, Williams P, Murunga S, Thitiri J, Ellis S, Correira E, Nyaoke B, Kipper K, van der Anker J, Sharland M, Berkley JA, Standing JF (2021) IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. J Antimicrob Chemother 76:1855–1864
pubmed: 33855449
pmcid: 8212774
doi: 10.1093/jac/dkab083
Stockmann C, Barrett JS, Roberts JK, Sherwin CMT (2015) Use of modeling and simulation in the design and conduct of pediatric clinical trials and the optimization of individualized dosing regimens. CPT Pharmacometrics Syst Pharmacol 4:630–640
pubmed: 26783499
pmcid: 4716585
doi: 10.1002/psp4.12038
Germovsek E, Barker CIS, Sharland M, Standing J (2017) Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful? Br J Clin Pharmacol 83:777–790
pubmed: 27767204
doi: 10.1111/bcp.13160
Darlow CA, Hope W (2022) Correction to: flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. J Antimicrob Chemother 77:2049
pubmed: 35640879
pmcid: 9244209
doi: 10.1093/jac/dkac153
Wu Y-E, Zhao W (2022) 'Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants’-authors’ response. J Antimicrob Chemother 77:3525–3526
pubmed: 36205004
doi: 10.1093/jac/dkac335
Shang Z-H, Wu Y-E, Lv D-M, Zhang W, Liu W-Q, van den Anker J, Xu Y, Zhao W (2022) Optimal dose of cefotaxime in neonates with early-onset sepsis: a developmental pharmacokinetic model-based evaluation. Front Pharmacol Sept 7(13):916253
doi: 10.3389/fphar.2022.916253